JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

CDK4/6 inhibitors in combination with endocrine therapy are now used as front-line treatment for patients with estrogen-receptor positive (ER+) breast cancer. While this combination improves overall survival, the mechanisms of disease progression remain poorly understood. Here, we performed unbiased...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of experimental & clinical cancer research Jg. 44; H. 1; S. 244 - 24
Hauptverfasser:	Alexandrou, Sarah, Lee, Christine S., Fernandez, Kristine J., Wiharja, Celine E., Eshraghi, Leila, Reeves, John, Reed, Daniel A., Portman, Neil, Phan, Zoe, Milioli, Heloisa H., Nikolic, Iva, Cadell, Antonia L., Croucher, David R., Simpson, Kaylene J., Lim, Elgene, Hickey, Theresa E., Millar, Ewan K. A., Alves, Carla L., Ditzel, Henrik J., Caldon, C. Elizabeth
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 19.08.2025 BioMed Central Ltd Springer Nature B.V BMC
Schlagworte:	Animals Antimitotic agents Antineoplastic agents Apoptosis Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer Research Cancer therapies CDK4/6 inhibition Cell growth Cell Line, Tumor CRISPR Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - antagonists & inhibitors Cyclin-dependent kinases Cytokeratin Development and progression Drug Resistance, Neoplasm Endocrine therapy ER+ breast cancer Estrogen Female Genomes Genomics Humans Immunology JNK signalling Kinases MAP Kinase Signaling System - drug effects Medical research Metabolism Metastasis Mice Oncology Palbociclib Piperazines Plasmids Protein Kinase Inhibitors - pharmacology Pyridines - pharmacology Receptors, Estrogen - metabolism Tamoxifen - pharmacology Xenograft Model Antitumor Assays Endocrine therapy ER+ breast cancer JNK signalling Palbociclib CDK4/6 inhibition
ISSN:	1756-9966, 0392-9078, 1756-9966
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!